Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for advanced cervical cancer: immune combo shows promise

NCT ID NCT04300647

Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug combination (tiragolumab plus atezolizumab) against atezolizumab alone in 172 people with advanced or returning cervical cancer that has a specific marker (PD-L1-positive). The goal was to see if the combination could shrink tumors better. Participants received treatment until their cancer worsened or side effects became too severe. This is a disease control study, not a cure, as ongoing management is needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

172 people

The number who actually took part.

Started

Jun 2020

Finished

Feb 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed recurrent or persistent squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix after progression on or after 1-2 lines of prior systemic chemotherapy in the metastatic/recurrent setting that is not amenable to curative treatment with systemic chemotherapy, surgery, and/or radiotherapy * Radiologically-measurable disease * Eastern Cooperative Oncology Group (ECOG) performance Status of 0 or 1 * Cervical cancer tissue for study analysis (archival or fresh biopsy specimen) * Life expectancy of at least 12 weeks * Adequate hematologic and organ function * Female of childbearing potential must be willing to comply with adequate contraception Exclusion Criteria: * Treatment with investigational therapy with therapeutic intent within 28 days prior to randomization * Active or untreated central nervous system (CNS) or brain metastases * Active or history of autoimmune disease or immune deficiency * Active tuberculosis * Known, clinically significant liver disease * Severe infection per investigator judgement at the time of randomization or any active infection that, in the opinion of the investigator, could impact patient safety * Prior treatment with CD137 agonists or immune checkpoint blockade therapies, anti-CTLA-4, anti-TIGIT, anti-PD-1, and anti-PD-L1 therapeutic antibodies * Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to randomization * Treatment with systemic immunosuppressive medications within 1 week prior to randomization or anticipation of need for systemic immunosuppressive medication during study * Pregnant or breastfeeding woman * Known hypersensitivity to any component of the tiragolumab or atezolizumab formulations

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cervical cancer Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cervical cancer

Contacts and locations

Locations

  • Arizona Oncology Associates

    Phoenix, Arizona, 85016, United States

  • Asan Medical Center

    Seoul, 05505, South Korea

  • Augusta University

    Augusta, Georgia, 30912, United States

  • Bialostockie Centrum Onkologi

    Bialystok, 15-027, Poland

  • Centre Leon Berard

    Lyon, 69008, France

  • Centre Régional de Lutte Contre Le Cancer Val D'aurelle Paul Lamarque

    Montpellier, 34298, France

  • Centro Oncológico de Panamá

    Panama City, 0801, Panama

  • Chang Gung Medical Foundation, Linkou Branch

    Taoyuan City, 333, Taiwan

  • Chelyabisnk regional clinical center for oncology and nuclear medicine

    Chelyabinsk, Sverdlovsk Oblast, 454087, Russia

  • Christus Muguerza Clinica Vidriera

    Monterrey, Nuevo León, 64570, Mexico

  • Clinica CIMCA

    San José, 10103, Costa Rica

  • Clinica Ricardo Palma

    San Isidro, Lima 27, Peru

  • Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda

    São Paulo, São Paulo, 01317-000, Brazil

  • Complejo Hospitalario Universitario A Coruña (CHUAC)

    A Coruña, 15006, Spain

  • Gangnam Severance Hospital

    Seoul, 06273, South Korea

  • Gustave Roussy

    Villejuif, 94800, France

  • Hospital Araujo Jorge

    Goiânia, Goiás, 74605-070, Brazil

  • Hospital Nossa Senhora da Conceicao

    Porto Alegre, Rio Grande do Sul, 91350-200, Brazil

  • Hospital Sao Lucas - PUCRS

    Porto Alegre, Rio Grande do Sul, 90610-000, Brazil

  • Hospital Sao Rafael - HSR

    Salvador, Estado de Bahia, 41253-190, Brazil

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • Hospital Universitario La Paz

    Madrid, 28046, Spain

  • Hospital de Caridade de Ijui

    Ijuí, Rio Grande do Sul, 98700-000, Brazil

  • ICIMED Instituto de Investigación en Ciencias Médicas

    San José, 10108, Costa Rica

  • ICO - Site René Gauducheau

    Saint-Herblain, 44805, France

  • Institut Paoli Calmettes

    Marseille, 13009, France

  • Istituto Europeo Di Oncologia

    Milan, Lombardy, 20141, Italy

  • Istituto Tumori Napoli

    Naples, Campania, 80131, Italy

  • Jewish General Hospital

    Montreal, Quebec, H3T 1E2, Canada

  • Kaiser Permanente - Irvine

    Irvine, California, 92616, United States

  • Keimyung University Dongsan Hospital

    Daegu, 41931, South Korea

  • Korea Cancer Center Hospital of Korea Institute of Radiological and Medical Sciences

    Seoul, 01812, South Korea

  • London Regional Cancer Centre

    London, Ontario, N6A 4L6, Canada

  • MEDSI Clinical Hospital on Pyatnitsky Highway

    Moscow, Moscow Oblast, 143422, Russia

  • Mackay Memorial Hospital

    Taipei, Taiwan

  • Maharaj Nakorn Chiang Mai Hospital

    Muang, 50200, Thailand

  • Mater Misericordiae Limited

    South Brisbane, Queensland, 4101, Australia

  • McGill University Health Centre - Glen Site

    Montreal, Quebec, H4A 3J1, Canada

  • Narodowy Inst.Onkol.im.Sklodowskiej-Curie Panstw.Inst.Bad Gliwice

    Gliwice, 44-101, Poland

  • Narodowy Instytut Onkologii im. M.Sklodowskiej-Curie

    Warsaw, 02-781, Poland

  • National Taiwan University Hospital

    Taipei, 110, Taiwan

  • Oncology Associates of Oregon, P.C

    Eugene, Oregon, 97401, United States

  • Policlinico Universitario Agostino Gemelli

    Rome, Lazio, 00168, Italy

  • Princess Margaret Cancer Center

    Toronto, Ontario, M5G 1Z5, Canada

  • Republican Clinical Oncology Dispensary of Ministry of Healthcare of Tatarstan Republic

    Kazan', Tatarstan Republic, 420029, Russia

  • Royal Victoria Regional Health Centre

    Barrie, Ontario, L4M 6M2, Canada

  • Samsung Medical Center

    Seoul, 06351, South Korea

  • Sarah Cannon Research Institute

    London, W1G 6AD, United Kingdom

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, 03722, South Korea

  • Szpital Morski im.PCK

    Gdynia, 81-519, Poland

  • Taichung Veterans General Hospital

    Taichung, 40705, Taiwan

  • Taipei Veterans General Hospital

    Taipei, 11217, Taiwan

  • The Panama Clinic

    Panama City, 0832, Panama

  • Tomsk scientific research institute of oncology SO RAMN, PAD

    Tomsk, 634050, Russia

  • University College London Hospital

    London, NW1 - 2PG, United Kingdom

  • Volgograd Regional Clinical Oncology Dispensary

    Volgograd, 400138, Russia

  • Wielkopolskie Centrum Onkologii im. M. Sklodowskiej-Curie

    Poznan, 61-866, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.